Scott & White's Cancer Research Institute (CRI) is conducting a clinical trial that targets malignant T-cell lymphoma, a type of blood cancer. Lymphoma, which affects the white blood cells that normally protect against illness, is categorized either as B-cell or T-cell. About 85% of lymphomas are of B-cell origin, and 15% of T-cell origin. T-cell lymphomas are primarily chronic, but they do not respond well to chemotherapy. Therefore, says Arthur E. Frankel, M.D... 
More...
More...